---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-05-10T18:42:48.530475'
end_time: '2026-05-10T19:00:13.355501'
duration_seconds: 1044.83
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: BAG6
  gene_symbol: BAG6
  uniprot_accession: P46379
  protein_description: 'RecName: Full=Large proline-rich protein BAG6 {ECO:0000305};
    AltName: Full=BAG family molecular chaperone regulator 6; AltName: Full=BCL2-associated
    athanogene 6 {ECO:0000312|HGNC:HGNC:13919}; Short=BAG-6; AltName: Full=HLA-B-associated
    transcript 3 {ECO:0000303|PubMed:2156268}; AltName: Full=Protein G3; AltName:
    Full=Protein Scythe {ECO:0000303|PubMed:17403783};'
  gene_info: Name=BAG6 {ECO:0000312|HGNC:HGNC:13919}; Synonyms=BAT3 {ECO:0000303|PubMed:2156268},
    G3;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: BAG6. (IPR021925); Bag6_BAGS. (IPR048926); Ubiquitin-like_dom.
    (IPR000626); Ubiquitin-like_domsf. (IPR029071); Ubiquitin_CS. (IPR019954)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 29
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P46379
- **Protein Description:** RecName: Full=Large proline-rich protein BAG6 {ECO:0000305}; AltName: Full=BAG family molecular chaperone regulator 6; AltName: Full=BCL2-associated athanogene 6 {ECO:0000312|HGNC:HGNC:13919}; Short=BAG-6; AltName: Full=HLA-B-associated transcript 3 {ECO:0000303|PubMed:2156268}; AltName: Full=Protein G3; AltName: Full=Protein Scythe {ECO:0000303|PubMed:17403783};
- **Gene Information:** Name=BAG6 {ECO:0000312|HGNC:HGNC:13919}; Synonyms=BAT3 {ECO:0000303|PubMed:2156268}, G3;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BAG6. (IPR021925); Bag6_BAGS. (IPR048926); Ubiquitin-like_dom. (IPR000626); Ubiquitin-like_domsf. (IPR029071); Ubiquitin_CS. (IPR019954)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BAG6" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BAG6' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BAG6** (gene ID: BAG6, UniProt: P46379) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P46379
- **Protein Description:** RecName: Full=Large proline-rich protein BAG6 {ECO:0000305}; AltName: Full=BAG family molecular chaperone regulator 6; AltName: Full=BCL2-associated athanogene 6 {ECO:0000312|HGNC:HGNC:13919}; Short=BAG-6; AltName: Full=HLA-B-associated transcript 3 {ECO:0000303|PubMed:2156268}; AltName: Full=Protein G3; AltName: Full=Protein Scythe {ECO:0000303|PubMed:17403783};
- **Gene Information:** Name=BAG6 {ECO:0000312|HGNC:HGNC:13919}; Synonyms=BAT3 {ECO:0000303|PubMed:2156268}, G3;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BAG6. (IPR021925); Bag6_BAGS. (IPR048926); Ubiquitin-like_dom. (IPR000626); Ubiquitin-like_domsf. (IPR029071); Ubiquitin_CS. (IPR019954)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BAG6" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BAG6' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BAG6** (gene ID: BAG6, UniProt: P46379) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

# Research Report: Human BAG6 (UniProt P46379; BAT3/Scythe) — Functional Annotation (2023–2024 prioritized)

## 0) Target verification (mandatory)
The literature synthesized here explicitly refers to **human BAG6** using the aliases **BAT3** and **Scythe**, and describes functions/complexes consistent with UniProt **P46379** (N-terminal ubiquitin-like domain; BAG6/Bag6_BAGS regions; cytosolic PQC and TA-protein handling). For example, BAG6 is discussed as part of the mammalian **TRC/GET tail-anchored pathway** and as a cytosolic quality-control holdase and ubiquitin-ligase adaptor in multiple studies (hagiwara2023proteotoxicstressesstimulate pages 1-3, hagiwara2023proteotoxicstressesstimulate pages 3-5, miyauchi2023bag6supportsstress pages 1-2, zhou2024bag6inhibitsinfluenza pages 2-4, guna2018transmembranedomainrecognition pages 4-6).

## 1) Key concepts and definitions (current understanding)

### 1.1 Tail-anchored (TA) proteins and the TRC/GET pathway
**Tail-anchored proteins** are membrane proteins with a single hydrophobic transmembrane domain (TMD) near the C-terminus that typically insert post-translationally into the ER membrane. In mammals, TA protein targeting is carried out by the **TRC40 pathway** (homologous to the yeast GET pathway). BAG6 is embedded in this pathway as both a **substrate-holding factor** and a **quality-control adaptor** (guna2018transmembranedomainrecognition pages 4-6).

A key synthesis is that BAG6’s **C-terminal region** is a structural part of the substrate-loading complex that bridges **UBL4A/SGTA** to **TRC35/TRC40**, while the **N-terminal ubiquitin-like (UBL) domain** recruits ubiquitination machinery (notably RNF126) to route failed clients to proteasomal degradation (guna2018transmembranedomainrecognition pages 4-6).

### 1.2 Cytosolic protein quality control (PQC) for hydrophobic/mislocalized proteins
BAG6 is widely characterized as a **chaperone/holdase** that binds exposed hydrophobic segments of nascent or mislocalized proteins, preventing aggregation and enabling either productive targeting or degradative routing (abildgaard2020cochaperonesintargeting pages 9-11, abildgaard2020cochaperonesintargeting pages 21-23). Mechanistically, BAG6 links client capture to **ubiquitin-mediated proteasomal degradation** via recruitment of E3 ligases (e.g., RNF126) and via interactions enabling delivery to the proteasome (guna2018transmembranedomainrecognition pages 4-6, abildgaard2020cochaperonesintargeting pages 9-11).

### 1.3 “Triage” as a stress-sensitive decision point
Recent work emphasizes that BAG6 participates in **stress-sensitive triage**: allocating capacity between (i) biogenesis of TA proteins via TRC machinery and (ii) elimination of defective/aggregation-prone proteins. Under proteotoxic stress, BAG6 complex composition can shift, consistent with triage between these fates (hagiwara2023proteotoxicstressesstimulate pages 3-5, hagiwara2023proteotoxicstressesstimulate pages 10-12).

## 2) Molecular functions, domains, and interaction partners

### 2.1 Core complexes and partners
**Canonical TA targeting / TRC pathway partners**: BAG6 forms or participates in assemblies including **UBL4A, TRC35, TRC40**, and interacts functionally with **SGTA** and the ER insertase **WRB–CAML** in TA handover and insertion (roboti2022mitochondrialantiviralsignallingprotein pages 1-2, guna2018transmembranedomainrecognition pages 4-6, abildgaard2020cochaperonesintargeting pages 9-11).

**Quality-control and degradation partners**: BAG6’s UBL domain can recruit the E3 ligase **RNF126** (review-level synthesis), and stress can increase BAG6 association with **UBQLN4** in the context of proteasome inhibition (hagiwara2023proteotoxicstressesstimulate pages 3-5, guna2018transmembranedomainrecognition pages 4-6, abildgaard2020cochaperonesintargeting pages 9-11).

### 2.2 Biochemical and quantitative evidence for complex stability/remodeling (2023)
A notable quantitative contribution from 2023 is the demonstration that BAG6–UBL4A binding is extremely tight in vitro (**Kd ~2.2 nM**) and that estimated cellular concentrations in HEK293T are high (**~720 nM BAG6**; **~700 nM UBL4A**), yet proteotoxic stress still induces dissociation in cells—supporting dynamic remodeling rather than a static assembly (hagiwara2023proteotoxicstressesstimulate pages 3-5).

## 3) Subcellular localization and where BAG6 acts
BAG6 is principally discussed as acting in the **cytosol** at the interface of newly synthesized hydrophobic proteins, TA substrate capture, and proteasomal delivery, with functional coupling to ER insertion machinery (TRC40; WRB–CAML) (roboti2022mitochondrialantiviralsignallingprotein pages 1-2, guna2018transmembranedomainrecognition pages 4-6, abildgaard2020cochaperonesintargeting pages 9-11). It can also appear in **ubiquitin-positive inclusions/aggregates** under proteotoxic stress conditions, consistent with a PQC role when aggregation risk is high (hagiwara2023proteotoxicstressesstimulate pages 3-5).

Some mechanistic evidence indicates BAG6 is a **nucleocytoplasmic shuttling protein**, with cytosolic retention promoted by GET4 masking a nuclear localization sequence; disease-linked perturbations of GET4 interactions can alter localization (wang2021analysisofthe pages 80-84).

## 4) Biological pathways and experimentally supported roles

### 4.1 TA protein biogenesis and hydrophobic-client triage
A high-impact conceptual model is that BAG6 preferentially binds long hydrophobic TMDs with slow off-rate, sequestering clients that fail timely membrane engagement and routing them toward ubiquitination and proteasomal degradation, while still supporting handover to the TRC40 targeting apparatus for productive TA insertion (guna2018transmembranedomainrecognition pages 4-6).

### 4.2 Stress-driven remodeling of TA-recognition vs degradative PQC (2023)
Hagiwara et al. (Biochemical Journal; Oct 2023; https://doi.org/10.1042/BCJ20230267) show that proteotoxic stressors (including polyQ aggregation, proteasome inhibition, mitochondrial depolarization) promote **dissociation of UBL4A from BAG6**, and propose this as a **triage mechanism** prioritizing degradation over TA synthesis under stress (hagiwara2023proteotoxicstressesstimulate pages 3-5, hagiwara2023proteotoxicstressesstimulate pages 10-12). The authors explicitly connect disruption of BAG6–UBL4A to impaired TA protein synthesis needed for vesicular trafficking and discuss relevance to aggregate-driven neurodegeneration mechanisms (hagiwara2023proteotoxicstressesstimulate pages 10-12).

### 4.3 Innate immunity: BAG6 regulation of MAVS TA client pool (2022; mechanistic bridge to immunity)
Roboti et al. (Journal of Cell Science; May 2022; https://doi.org/10.1242/jcs.259596) identify the mitochondrial TA protein **MAVS** as an endogenous client of both **SGTA** and the **BAG6 complex**, and propose that BAG6 binds a cytosolic pool of MAVS prior to misinsertion and retrieval, with the BAG6-associated fraction responding dynamically to innate immune activation (roboti2022mitochondrialantiviralsignallingprotein pages 1-2).

### 4.4 Novel role in actin cytoskeleton control via RhoA stabilization (2023)
Miyauchi et al. (Molecular Biology of the Cell; Apr 2023; https://doi.org/10.1091/mbc.e22-08-0355) identify BAG6 as a factor required to stabilize endogenous **RhoA** and thereby support **stress fiber formation**, focal adhesion assembly, and cell migration. Mechanistically, BAG6 depletion increases association of GDP-bound RhoA with **CUL3-based E3 ligases**, increasing RhoA polyubiquitination and degradation (miyauchi2023bag6supportsstress pages 1-2, miyauchi2023bag6supportsstress pages 11-13). The study includes quantitative ubiquitination comparisons with **p < 0.05** (miyauchi2023bag6supportsstress pages 11-13).

### 4.5 Viral restriction: influenza A PB2 degradation and RdRp assembly interference (2024)
Zhou et al. (PLOS Pathogens; Mar 2024; https://doi.org/10.1371/journal.ppat.1012110) identify BAG6 as a host restriction factor for influenza A virus (IAV). Mechanistically, BAG6 binds the **N-terminus of PB2**, competes with **PB1** for RdRp assembly, and promotes **K48-linked ubiquitination** and degradation of PB2, including mapping PB2 ubiquitination at **K189** (zhou2024bag6inhibitsinfluenza pages 1-2).

**Effect sizes and in vivo relevance (key statistics):**
* In vitro, BAG6 overexpression reduced infectious titers by **~10–15-fold** (TCID50), while BAG6 loss increased titers **up to ~10-fold** (zhou2024bag6inhibitsinfluenza pages 2-4).
* In mice, BAG6 knockdown increased disease severity with **~40% mortality vs 0%** in controls (by 8 dpi) and **~10-fold higher lung viral loads** at 3 and 5 dpi (zhou2024bag6inhibitsinfluenza pages 4-7).
* Domain requirements: antiviral activity required BAG6 N-terminus including **UBL domain (aa 17–92)** plus a **PB2-binding region (aa 124–186)** (zhou2024bag6inhibitsinfluenza pages 1-2). These quantitative/doman-mapping results are also supported by the extracted figure panels (zhou2024bag6inhibitsinfluenza media f7dcee05).

## 5) Recent developments and latest research highlights (2023–2024 focus)

1. **Stress-sensitive disassembly of BAG6–UBL4A despite nanomolar affinity** suggests regulated triage and provides a mechanistic link between proteotoxic stress and impairment of TA biogenesis/vesicular trafficking (Hagiwara 2023) (hagiwara2023proteotoxicstressesstimulate pages 3-5, hagiwara2023proteotoxicstressesstimulate pages 10-12).
2. **Expansion of client scope to soluble signaling proteins**: BAG6 acts as a GDP-RhoA holdase that protects against E3 access and degradation, connecting BAG6 PQC logic to cytoskeletal dynamics and migration (Miyauchi 2023) (miyauchi2023bag6supportsstress pages 1-2, miyauchi2023bag6supportsstress pages 11-13).
3. **Direct antiviral effector mechanism**: BAG6 can function as an influenza restriction factor by driving degradation of a viral polymerase subunit and disrupting polymerase assembly, with large-magnitude in vitro and in vivo effects (Zhou 2024) (zhou2024bag6inhibitsinfluenza pages 2-4, zhou2024bag6inhibitsinfluenza pages 1-2, zhou2024bag6inhibitsinfluenza pages 4-7, zhou2024bag6inhibitsinfluenza media f7dcee05).
4. **Tumor biology via extracellular vesicles (EVs)**: BAG6 is implicated as a tumor-suppressive regulator in PDAC via suppression of IL33-presenting EV release and mast-cell activation (Alhamwe 2024) (alhamwe2024bag6restrictspancreatic pages 1-2, alhamwe2024bag6restrictspancreatic pages 8-10).
5. **Repair-associated gene expression signatures**: In an emphysema/COPD repair model, Bag6 is among top differentially expressed genes in response to liver growth factor treatment, suggesting involvement in inflammation/immune-response regulation during repair (Carretero 2024) (carretero2024differentiallunggene pages 8-10).

## 6) Current applications and real-world implementations

### 6.1 Oncology: biomarker and therapy-stratification concepts (PDAC)
Alhamwe et al. (Cellular & Molecular Immunology; Jun 2024; https://doi.org/10.1038/s41423-024-01195-1) report that Bag6 deficiency accelerates PDAC tumor growth in an EV-dependent and mast-cell–dependent manner, and propose a translational rationale for considering **mast-cell depletion (imatinib)** in patients stratified by **low BAG6 expression** and high mast-cell infiltration (alhamwe2024bag6restrictspancreatic pages 1-2). They also discuss pharmacologic inhibition of EV release (GW4869) in vivo as a rescue approach (alhamwe2024bag6restrictspancreatic pages 11-12). The study notes that **high BAG6 gene expression and high plasma BAG6 protein** are associated with longer overall survival, supporting biomarker relevance (alhamwe2024bag6restrictspancreatic pages 1-2).

### 6.2 Host-directed antivirals / biomarkers (influenza A)
Zhou et al. (2024) show that BAG6 manipulation strongly affects viral replication (order-of-magnitude changes in titers) and disease outcomes in mice, implying BAG6-regulated pathways (ubiquitin-dependent PB2 turnover and polymerase assembly) could be explored for host-directed antiviral strategies or as biomarkers of susceptibility/severity (zhou2024bag6inhibitsinfluenza pages 2-4, zhou2024bag6inhibitsinfluenza pages 4-7).

### 6.3 Disease modeling and repair-response markers (COPD model)
In a cigarette-smoke emphysema model with liver growth factor treatment, Bag6 is upregulated with **fold change 2.114** (FDR **3.69E-03**) and qRT-PCR validation showing **1.390 ± 0.119 vs 1.061 ± 0.138; p = 0.0087**, suggesting Bag6 as part of a repair-associated gene signature in this model (Carretero 2024; Aug 22, 2024; https://doi.org/10.1371/journal.pone.0309166) (carretero2024differentiallunggene pages 8-10).

## 7) Expert opinions and analysis (authoritative synthesis)

### 7.1 BAG6 as a metazoan “quality-control embellishment” of TA targeting
A widely cited synthesis (Guna & Hegde, Current Biology; Apr 23, 2018; https://doi.org/10.1016/j.cub.2018.02.004) frames BAG6 as a metazoan-specific adaptor that integrates TA targeting with a “fail-safe” degradative arm: BAG6 captures long hydrophobic TMDs with slow off-rate, recruits RNF126 via its UBL domain for ubiquitination, and uses its C-terminus to connect UBL4A/SGTA with TRC35/TRC40 to enable either insertion or disposal (guna2018transmembranedomainrecognition pages 4-6).

### 7.2 BAG6 as a proteasome-delivery co-chaperone/holdase
Abildgaard et al. (Biomolecules; Aug 2020; https://doi.org/10.3390/biom10081141) emphasize BAG6 as a holdase that can function largely independently of Hsp70, acting as part of a **BAG6–UBL4A–TRC35** complex that can recruit ubiquitination machinery (RNF126) and interact with the proteasome to deliver substrates for degradation (abildgaard2020cochaperonesintargeting pages 9-11).

## 8) Relevant statistics and quantitative data (recent studies)

* **BAG6–UBL4A biochemical affinity and abundance:** in vitro Kd **2.2 nM**; estimated cellular concentrations **~720 nM BAG6** and **~700 nM UBL4A** (Hagiwara 2023) (hagiwara2023proteotoxicstressesstimulate pages 3-5).
* **Influenza A restriction (in vitro):** BAG6 overexpression yields **~10–15-fold** lower titers; BAG6 loss yields **up to ~10-fold** higher titers (Zhou 2024) (zhou2024bag6inhibitsinfluenza pages 2-4).
* **Influenza A restriction (in vivo):** BAG6 knockdown mice show **~40% mortality vs 0%** and **~10-fold higher lung viral loads** (Zhou 2024) (zhou2024bag6inhibitsinfluenza pages 4-7). These outcomes are visualized in extracted figure panels (zhou2024bag6inhibitsinfluenza media f7dcee05).
* **COPD model gene expression:** Bag6 in top DEGs with **FC 2.114** and **FDR 3.69E-03**; qRT-PCR validation **p=0.0087** (Carretero 2024) (carretero2024differentiallunggene pages 8-10).
* **RhoA ubiquitination phenotype:** BAG6 knockdown enhances RhoA polyubiquitination, with quantitative comparisons reported with **p < 0.05** (Miyauchi 2023) (miyauchi2023bag6supportsstress pages 11-13).

## 9) Disease associations (database-level summary)
Open Targets reports BAG6 target–disease association evidence for **neurodegenerative disease** based on CRISPRi neuronal screen studies (PubMed **34031600**) (OpenTargets Search: -BAG6). This is hypothesis-generating and should be interpreted as functional-genomics evidence rather than direct causal mechanistic proof.

## 10) Consolidated functional summary table
The table below summarizes BAG6’s best-supported functional modules (partners, locations, mechanisms, and recent quantitative evidence).

| Function/module | Key partners/complex | Cellular location | Mechanism (1 sentence) | Key recent evidence (2023-2024) with effect sizes/statistics when available | Key foundational evidence/reviews |
|---|---|---|---|---|---|
| Tail-anchored (TA) protein capture and handoff | BAG6–UBL4A–TRC35 complex with SGTA, TRC40, WRB–CAML | Cytosol; ER-targeting interface | BAG6 acts as a hydrophobic-client holdase and scaffold that links SGTA-bound TA clients to TRC40-mediated ER insertion while retaining failed clients for triage. (roboti2022mitochondrialantiviralsignallingprotein pages 1-2, guna2018transmembranedomainrecognition pages 4-6, abildgaard2020cochaperonesintargeting pages 9-11) | Proteotoxic stress and polyQ inclusions trigger UBL4A dissociation from BAG6; BAG6–UBL4A affinity is strong in vitro (Kd 2.2 nM), and estimated cellular concentrations are ~720 nM BAG6 and ~700 nM UBL4A, supporting a normally stable TA-recognition complex that is remodeled under stress. (hagiwara2023proteotoxicstressesstimulate pages 1-3, hagiwara2023proteotoxicstressesstimulate pages 3-5) | Reviews place BAG6 as a metazoan quality-control layer in the TRC40 pathway, with its C-terminus bridging UBL4A/SGTA and TRC35/TRC40 during TA targeting. (guna2018transmembranedomainrecognition pages 4-6, abildgaard2020cochaperonesintargeting pages 9-11) |
| Cytosolic PQC and degradation of hydrophobic/mislocalized proteins | RNF126, UBQLN4, SGTA, proteasome | Cytosol; proteasome-associated; aggregate-prone compartments | BAG6 captures hydrophobic or mislocalized clients, keeps them soluble, recruits ubiquitination machinery, and promotes proteasomal delivery/degradation. (guna2018transmembranedomainrecognition pages 4-6, abildgaard2020cochaperonesintargeting pages 9-11, abildgaard2020cochaperonesintargeting pages 21-23) | Under proteasome inhibition, soluble BAG6 loses associated UBL4A but gains UBQLN4, indicating stress-dependent remodeling from TA biogenesis toward degradative PQC; BAG6 also colocalizes with ubiquitin-positive inclusions. (hagiwara2023proteotoxicstressesstimulate pages 3-5) | BAG6’s N-terminal UBL recruits RNF126, and reviews describe BAG6 as a holdase for TA proteins, defective nascent chains, ERAD substrates, and mislocalized membrane proteins. (guna2018transmembranedomainrecognition pages 4-6, abildgaard2020cochaperonesintargeting pages 9-11, abildgaard2020cochaperonesintargeting pages 21-23) |
| ERAD-linked substrate processing | SGTA, p97 pathway components, RNF126 | Cytosol and ER-proximal quality-control interface | BAG6 helps route failed membrane/secretory protein biogenesis products and certain ERAD substrates into ubiquitin-proteasome degradation rather than productive insertion. (abildgaard2020cochaperonesintargeting pages 9-11, roboti2022mitochondrialantiviralsignallingprotein pages 15-15, you2020paqr9modulatesbag6mediated pages 15-16) | 2023 review context continues to position BAG6 in substrate processing and ER-proximal PQC, though BAG6-specific quantitative 2023–2024 ERAD effect sizes were not provided in the retrieved excerpts. (abildgaard2020cochaperonesintargeting pages 9-11, hagiwara2023proteotoxicstressesstimulate pages 14-15) | Reviews summarize BAG6 as coupling client capture, ligase recruitment, and proteasome targeting for ERAD-like outcomes after failed membrane engagement. (guna2018transmembranedomainrecognition pages 4-6, abildgaard2020cochaperonesintargeting pages 9-11) |
| Stress-responsive remodeling of the BAG6 complex | UBL4A, TRC35, TRC40, UBQLN4 | Cytosol; insoluble aggregates under stress | Proteotoxic stress redistributes BAG6 complexes by dissociating UBL4A and favoring aggregate-associated/degradative BAG6 states. (hagiwara2023proteotoxicstressesstimulate pages 1-3, hagiwara2023proteotoxicstressesstimulate pages 3-5) | PolyQ inclusions, proteasome inhibition, and mitochondrial depolarization reduce BAG6–UBL4A association; overexpressed UBL4A suppresses BAG6 translocation into insoluble aggregates. (hagiwara2023proteotoxicstressesstimulate pages 3-5) | Foundational models of BAG6 explain this as a triage switch between TA targeting and degradation of hydrophobic clients. (guna2018transmembranedomainrecognition pages 4-6, abildgaard2020cochaperonesintargeting pages 9-11) |
| Innate immunity-linked TA client control | MAVS with SGTA and BAG6–UBL4A–TRC35 | Cytosolic pool; ER and mitochondrial-signaling membrane interface | BAG6 binds a cytosolic pool of the mitochondrial TA protein MAVS before misinsertion/retrieval, thereby modulating the fraction available for antiviral signaling. (roboti2022mitochondrialantiviralsignallingprotein pages 1-2) | BioID2 proximity labeling identified MAVS as a high-confidence SGTA interactor (BFDR < 0.05), and BAG6-associated MAVS changed dynamically during innate immune activation. (roboti2022mitochondrialantiviralsignallingprotein pages 1-2) | This extends the established BAG6 client-triage model from generic TA proteins to an endogenous immune signaling TA client. (roboti2022mitochondrialantiviralsignallingprotein pages 1-2, guna2018transmembranedomainrecognition pages 4-6) |
| Direct antiviral restriction of influenza A virus | Viral PB2, PB1/RdRp complex | Predominantly cytosolic/nuclear viral polymerase context | BAG6 binds PB2, competes with PB1 for polymerase assembly, and promotes K48-linked ubiquitination-dependent PB2 degradation to suppress IAV replication. (zhou2024bag6inhibitsinfluenza pages 2-4, zhou2024bag6inhibitsinfluenza pages 1-2) | Overexpression decreased IAV titers by ~10–15-fold across H1N1, H7N9, H9N2, and H5N1; BAG6 loss increased titers up to ~10-fold; in mice, BAG6 knockdown caused ~40% mortality by 8 dpi versus 0% in controls and ~10-fold higher lung viral loads. Figure review also mapped required BAG6 regions to the UBL domain (aa 17–92) plus a PB2-binding region (aa 124–186). (zhou2024bag6inhibitsinfluenza pages 2-4, zhou2024bag6inhibitsinfluenza pages 4-7, zhou2024bag6inhibitsinfluenza media f7dcee05) | Recent primary work builds on broader BAG6 chaperone/PQC functions rather than a separate foundational antiviral literature in the retrieved corpus. (abildgaard2020cochaperonesintargeting pages 9-11, abildgaard2020cochaperonesintargeting pages 21-23) |
| Cytoskeletal regulation via small GTPase stabilization | RhoA, CUL3-based ubiquitin ligases | Cytosol; stress fibers/focal adhesions | BAG6 acts as a holdase for GDP-bound RhoA, limiting its association with CUL3 ligases and thereby preserving RhoA-dependent actin assembly. (miyauchi2023bag6supportsstress pages 1-2) | BAG6 depletion increased RhoA polyubiquitination and degradation, impairing stress fibers, focal adhesion assembly, and cell migration; RhoA re-expression rescued the phenotype. (miyauchi2023bag6supportsstress pages 1-2) | This expands BAG6 client selectivity beyond membrane-hydrophobic clients to a soluble signaling protein stabilized through a related anti-degradation holdase mechanism. (miyauchi2023bag6supportsstress pages 1-2, abildgaard2020cochaperonesintargeting pages 21-23) |
| Tumor microenvironment and extracellular vesicle regulation | p53, CBP/p300, ESCRT machinery, IL33-positive EVs, mast cells | Cytosol/nucleus-linked vesicle biogenesis pathway; extracellular vesicles; tumor microenvironment | BAG6 restrains pancreatic tumor progression by promoting EV biogenesis programs that prevent release of IL33-presenting EVs that activate mast cells and remodel the TME. (alhamwe2024bag6restrictspancreatic pages 1-2) | In PDAC models, Bag6 deficiency accelerated subcutaneous and orthotopic tumor growth in an EV-dependent manner; high BAG6 gene expression and plasma BAG6 associated with longer overall survival, and imatinib-mediated mast-cell depletion reduced tumor growth in BAG6-low contexts. (alhamwe2024bag6restrictspancreatic pages 1-2) | The study leverages prior evidence that BAG6 regulates membrane vesicle trafficking, EV cargo sorting, and immune-cell activation. (alhamwe2024bag6restrictspancreatic pages 1-2) |
| Nuclear-cytoplasmic shuttling and localization control | GET4, UBL4A, FBXO7 | Cytosol and nucleus | BAG6 is a nucleocytoplasmic shuttling protein whose retention in the cytosol is promoted by GET4 masking its nuclear localization sequence. (wang2021analysisofthe pages 80-84) | Dissertation-level mechanistic evidence reports that FBXO7-enhanced GET4 ubiquitination increases GET4–BAG6 binding and shifts BAG6 cytoplasmic localization; disease-associated FBXO7 variants weaken this control. (wang2021analysisofthe pages 80-84) | This localization logic fits BAG6’s established need to remain cytosolic for TA targeting/PQC while retaining the capacity for alternative signaling roles. (wang2021analysisofthe pages 80-84, guna2018transmembranedomainrecognition pages 4-6) |


*Table: This table summarizes the best-supported functional modules of human BAG6 (UniProt P46379), integrating core mechanistic roles, partners, locations, and recent 2023-2024 evidence with quantitative findings where available. It is useful for quickly distinguishing BAG6’s foundational tail-anchored protein/PQC functions from newer roles in antiviral defense, cytoskeletal regulation, and tumor biology.*

## 11) Key references (URLs and publication dates)
* Zhou Y. et al. **“BAG6 inhibits influenza A virus replication…”** PLOS Pathogens. **Mar 2024**. https://doi.org/10.1371/journal.ppat.1012110 (zhou2024bag6inhibitsinfluenza pages 2-4, zhou2024bag6inhibitsinfluenza pages 4-7)
* Alhamwe B.A. et al. **“BAG6 restricts pancreatic cancer progression…”** Cellular & Molecular Immunology. **Jun 2024**. https://doi.org/10.1038/s41423-024-01195-1 (alhamwe2024bag6restrictspancreatic pages 1-2)
* Carretero L.S. et al. **“Differential lung gene expression identified … Bag6 …”** PLOS ONE. **Aug 22, 2024**. https://doi.org/10.1371/journal.pone.0309166 (carretero2024differentiallunggene pages 8-10)
* Hagiwara T. et al. **“Proteotoxic stresses stimulate dissociation of UBL4A …”** Biochemical Journal. **Oct 2023**. https://doi.org/10.1042/BCJ20230267 (hagiwara2023proteotoxicstressesstimulate pages 3-5, hagiwara2023proteotoxicstressesstimulate pages 10-12)
* Miyauchi M. et al. **“BAG6 supports stress fiber formation …”** Molecular Biology of the Cell. **Apr 1, 2023**. https://doi.org/10.1091/mbc.e22-08-0355 (miyauchi2023bag6supportsstress pages 11-13)
* Roboti P. et al. **“Mitochondrial antiviral-signalling protein is a client …”** Journal of Cell Science. **May 2022**. https://doi.org/10.1242/jcs.259596 (roboti2022mitochondrialantiviralsignallingprotein pages 1-2)
* Abildgaard A.B. et al. **“Co-Chaperones in Targeting and Delivery …”** Biomolecules. **Aug 2020**. https://doi.org/10.3390/biom10081141 (abildgaard2020cochaperonesintargeting pages 9-11)
* Guna A., Hegde R.S. **“Transmembrane Domain Recognition …”** Current Biology. **Apr 23, 2018**. https://doi.org/10.1016/j.cub.2018.02.004 (guna2018transmembranedomainrecognition pages 4-6)

## 12) Limitations of this synthesis
Some frequently discussed BAG6 roles (e.g., antigen presentation, apoptosis regulation, mitophagy/autophagy) are mentioned in the retrieved PDAC/virology papers as contextual background but were not comprehensively supported with primary mechanistic excerpts within the currently retrieved text segments. Accordingly, the report emphasizes roles with direct mechanistic and/or quantitative support in the available evidence corpus.


References

1. (hagiwara2023proteotoxicstressesstimulate pages 1-3): Takumi Hagiwara, Ryosuke Minami, Chizuru Ushio, Naoto Yokota, and Hiroyuki Kawahara. Proteotoxic stresses stimulate dissociation of ubl4a from the tail-anchored protein recognition complex. Biochemical Journal, 480:1583-1598, Oct 2023. URL: https://doi.org/10.1042/bcj20230267, doi:10.1042/bcj20230267. This article has 0 citations and is from a domain leading peer-reviewed journal.

2. (hagiwara2023proteotoxicstressesstimulate pages 3-5): Takumi Hagiwara, Ryosuke Minami, Chizuru Ushio, Naoto Yokota, and Hiroyuki Kawahara. Proteotoxic stresses stimulate dissociation of ubl4a from the tail-anchored protein recognition complex. Biochemical Journal, 480:1583-1598, Oct 2023. URL: https://doi.org/10.1042/bcj20230267, doi:10.1042/bcj20230267. This article has 0 citations and is from a domain leading peer-reviewed journal.

3. (miyauchi2023bag6supportsstress pages 1-2): Maho Miyauchi, Reina Matsumura, and Hiroyuki Kawahara. Bag6 supports stress fiber formation by preventing the ubiquitin-mediated degradation of rhoa. Molecular Biology of the Cell, Apr 2023. URL: https://doi.org/10.1091/mbc.e22-08-0355, doi:10.1091/mbc.e22-08-0355. This article has 7 citations and is from a domain leading peer-reviewed journal.

4. (zhou2024bag6inhibitsinfluenza pages 2-4): Yong Zhou, Tian Li, Yunfan Zhang, Nianzhi Zhang, Yuxin Guo, Xiaoyi Gao, Wenjing Peng, Sicheng Shu, Chuankuo Zhao, Di Cui, Honglei Sun, Yipeng Sun, Jinhua Liu, Jun Tang, Rui Zhang, and Juan Pu. Bag6 inhibits influenza a virus replication by inducing viral polymerase subunit pb2 degradation and perturbing rdrp complex assembly. PLOS Pathogens, 20:e1012110, Mar 2024. URL: https://doi.org/10.1371/journal.ppat.1012110, doi:10.1371/journal.ppat.1012110. This article has 13 citations and is from a highest quality peer-reviewed journal.

5. (guna2018transmembranedomainrecognition pages 4-6): Alina Guna and Ramanujan S. Hegde. Transmembrane domain recognition during membrane protein biogenesis and quality control. Current Biology, 28:R498-R511, Apr 2018. URL: https://doi.org/10.1016/j.cub.2018.02.004, doi:10.1016/j.cub.2018.02.004. This article has 151 citations and is from a highest quality peer-reviewed journal.

6. (abildgaard2020cochaperonesintargeting pages 9-11): Amanda B. Abildgaard, Sarah K. Gersing, Sven Larsen-Ledet, Sofie V. Nielsen, Amelie Stein, Kresten Lindorff-Larsen, and Rasmus Hartmann-Petersen. Co-chaperones in targeting and delivery of misfolded proteins to the 26s proteasome. Biomolecules, 10:1141, Aug 2020. URL: https://doi.org/10.3390/biom10081141, doi:10.3390/biom10081141. This article has 54 citations.

7. (abildgaard2020cochaperonesintargeting pages 21-23): Amanda B. Abildgaard, Sarah K. Gersing, Sven Larsen-Ledet, Sofie V. Nielsen, Amelie Stein, Kresten Lindorff-Larsen, and Rasmus Hartmann-Petersen. Co-chaperones in targeting and delivery of misfolded proteins to the 26s proteasome. Biomolecules, 10:1141, Aug 2020. URL: https://doi.org/10.3390/biom10081141, doi:10.3390/biom10081141. This article has 54 citations.

8. (hagiwara2023proteotoxicstressesstimulate pages 10-12): Takumi Hagiwara, Ryosuke Minami, Chizuru Ushio, Naoto Yokota, and Hiroyuki Kawahara. Proteotoxic stresses stimulate dissociation of ubl4a from the tail-anchored protein recognition complex. Biochemical Journal, 480:1583-1598, Oct 2023. URL: https://doi.org/10.1042/bcj20230267, doi:10.1042/bcj20230267. This article has 0 citations and is from a domain leading peer-reviewed journal.

9. (roboti2022mitochondrialantiviralsignallingprotein pages 1-2): Peristera Roboti, Craig Lawless, and Stephen High. Mitochondrial antiviral-signalling protein is a client of the bag6 protein quality control complex. Journal of Cell Science, May 2022. URL: https://doi.org/10.1242/jcs.259596, doi:10.1242/jcs.259596. This article has 1 citations and is from a domain leading peer-reviewed journal.

10. (wang2021analysisofthe pages 80-84): Quan Wang. Analysis of the interaction of the parkinsonism-associated protein fbxo7 with the bag6 complex. Dissertation, Jan 2021. URL: https://doi.org/10.18154/rwth-2022-00532, doi:10.18154/rwth-2022-00532. This article has 0 citations.

11. (miyauchi2023bag6supportsstress pages 11-13): Maho Miyauchi, Reina Matsumura, and Hiroyuki Kawahara. Bag6 supports stress fiber formation by preventing the ubiquitin-mediated degradation of rhoa. Molecular Biology of the Cell, Apr 2023. URL: https://doi.org/10.1091/mbc.e22-08-0355, doi:10.1091/mbc.e22-08-0355. This article has 7 citations and is from a domain leading peer-reviewed journal.

12. (zhou2024bag6inhibitsinfluenza pages 1-2): Yong Zhou, Tian Li, Yunfan Zhang, Nianzhi Zhang, Yuxin Guo, Xiaoyi Gao, Wenjing Peng, Sicheng Shu, Chuankuo Zhao, Di Cui, Honglei Sun, Yipeng Sun, Jinhua Liu, Jun Tang, Rui Zhang, and Juan Pu. Bag6 inhibits influenza a virus replication by inducing viral polymerase subunit pb2 degradation and perturbing rdrp complex assembly. PLOS Pathogens, 20:e1012110, Mar 2024. URL: https://doi.org/10.1371/journal.ppat.1012110, doi:10.1371/journal.ppat.1012110. This article has 13 citations and is from a highest quality peer-reviewed journal.

13. (zhou2024bag6inhibitsinfluenza pages 4-7): Yong Zhou, Tian Li, Yunfan Zhang, Nianzhi Zhang, Yuxin Guo, Xiaoyi Gao, Wenjing Peng, Sicheng Shu, Chuankuo Zhao, Di Cui, Honglei Sun, Yipeng Sun, Jinhua Liu, Jun Tang, Rui Zhang, and Juan Pu. Bag6 inhibits influenza a virus replication by inducing viral polymerase subunit pb2 degradation and perturbing rdrp complex assembly. PLOS Pathogens, 20:e1012110, Mar 2024. URL: https://doi.org/10.1371/journal.ppat.1012110, doi:10.1371/journal.ppat.1012110. This article has 13 citations and is from a highest quality peer-reviewed journal.

14. (zhou2024bag6inhibitsinfluenza media f7dcee05): Yong Zhou, Tian Li, Yunfan Zhang, Nianzhi Zhang, Yuxin Guo, Xiaoyi Gao, Wenjing Peng, Sicheng Shu, Chuankuo Zhao, Di Cui, Honglei Sun, Yipeng Sun, Jinhua Liu, Jun Tang, Rui Zhang, and Juan Pu. Bag6 inhibits influenza a virus replication by inducing viral polymerase subunit pb2 degradation and perturbing rdrp complex assembly. PLOS Pathogens, 20:e1012110, Mar 2024. URL: https://doi.org/10.1371/journal.ppat.1012110, doi:10.1371/journal.ppat.1012110. This article has 13 citations and is from a highest quality peer-reviewed journal.

15. (alhamwe2024bag6restrictspancreatic pages 1-2): Bilal Alashkar Alhamwe, Viviane Ponath, Fahd Alhamdan, Bastian Dörsam, Clara Landwehr, Manuel Linder, Kim Pauck, Sarah Miethe, Holger Garn, Florian Finkernagel, Anna Brichkina, Matthias Lauth, Dinesh Kumar Tiwari, Malte Buchholz, Daniel Bachurski, Sabrina Elmshäuser, Andrea Nist, Thorsten Stiewe, Lisa Pogge von Strandmann, Witold Szymański, Vanessa Beutgen, Johannes Graumann, Julia Teply-Szymanski, Corinna Keber, Carsten Denkert, Ralf Jacob, Christian Preußer, and Elke Pogge von Strandmann. Bag6 restricts pancreatic cancer progression by suppressing the release of il33-presenting extracellular vesicles and the activation of mast cells. Cellular and Molecular Immunology, 21:918-931, Jun 2024. URL: https://doi.org/10.1038/s41423-024-01195-1, doi:10.1038/s41423-024-01195-1. This article has 28 citations and is from a peer-reviewed journal.

16. (alhamwe2024bag6restrictspancreatic pages 8-10): Bilal Alashkar Alhamwe, Viviane Ponath, Fahd Alhamdan, Bastian Dörsam, Clara Landwehr, Manuel Linder, Kim Pauck, Sarah Miethe, Holger Garn, Florian Finkernagel, Anna Brichkina, Matthias Lauth, Dinesh Kumar Tiwari, Malte Buchholz, Daniel Bachurski, Sabrina Elmshäuser, Andrea Nist, Thorsten Stiewe, Lisa Pogge von Strandmann, Witold Szymański, Vanessa Beutgen, Johannes Graumann, Julia Teply-Szymanski, Corinna Keber, Carsten Denkert, Ralf Jacob, Christian Preußer, and Elke Pogge von Strandmann. Bag6 restricts pancreatic cancer progression by suppressing the release of il33-presenting extracellular vesicles and the activation of mast cells. Cellular and Molecular Immunology, 21:918-931, Jun 2024. URL: https://doi.org/10.1038/s41423-024-01195-1, doi:10.1038/s41423-024-01195-1. This article has 28 citations and is from a peer-reviewed journal.

17. (carretero2024differentiallunggene pages 8-10): Laura Sánchez Carretero, Adele Chloe Cardeñosa Pérez, Germán Peces-Barba, and Sandra Pérez-Rial. Differential lung gene expression identified zscan2 and bag6 as novel tissue repair players in an experimental copd model. PLOS ONE, 19:e0309166, Aug 2024. URL: https://doi.org/10.1371/journal.pone.0309166, doi:10.1371/journal.pone.0309166. This article has 2 citations and is from a peer-reviewed journal.

18. (alhamwe2024bag6restrictspancreatic pages 11-12): Bilal Alashkar Alhamwe, Viviane Ponath, Fahd Alhamdan, Bastian Dörsam, Clara Landwehr, Manuel Linder, Kim Pauck, Sarah Miethe, Holger Garn, Florian Finkernagel, Anna Brichkina, Matthias Lauth, Dinesh Kumar Tiwari, Malte Buchholz, Daniel Bachurski, Sabrina Elmshäuser, Andrea Nist, Thorsten Stiewe, Lisa Pogge von Strandmann, Witold Szymański, Vanessa Beutgen, Johannes Graumann, Julia Teply-Szymanski, Corinna Keber, Carsten Denkert, Ralf Jacob, Christian Preußer, and Elke Pogge von Strandmann. Bag6 restricts pancreatic cancer progression by suppressing the release of il33-presenting extracellular vesicles and the activation of mast cells. Cellular and Molecular Immunology, 21:918-931, Jun 2024. URL: https://doi.org/10.1038/s41423-024-01195-1, doi:10.1038/s41423-024-01195-1. This article has 28 citations and is from a peer-reviewed journal.

19. (OpenTargets Search: -BAG6): Open Targets Query (-BAG6, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

20. (roboti2022mitochondrialantiviralsignallingprotein pages 15-15): Peristera Roboti, Craig Lawless, and Stephen High. Mitochondrial antiviral-signalling protein is a client of the bag6 protein quality control complex. Journal of Cell Science, May 2022. URL: https://doi.org/10.1242/jcs.259596, doi:10.1242/jcs.259596. This article has 1 citations and is from a domain leading peer-reviewed journal.

21. (you2020paqr9modulatesbag6mediated pages 15-16): Xue You, Yijun Lin, Yongfan Hou, Lijiao Xu, Qianqian Cao, and Yan Chen. Paqr9 modulates bag6-mediated protein quality control of mislocalized membrane proteins. Biochemical Journal, 477:477-489, Jan 2020. URL: https://doi.org/10.1042/bcj20190620, doi:10.1042/bcj20190620. This article has 10 citations and is from a domain leading peer-reviewed journal.

22. (hagiwara2023proteotoxicstressesstimulate pages 14-15): Takumi Hagiwara, Ryosuke Minami, Chizuru Ushio, Naoto Yokota, and Hiroyuki Kawahara. Proteotoxic stresses stimulate dissociation of ubl4a from the tail-anchored protein recognition complex. Biochemical Journal, 480:1583-1598, Oct 2023. URL: https://doi.org/10.1042/bcj20230267, doi:10.1042/bcj20230267. This article has 0 citations and is from a domain leading peer-reviewed journal.

## Citations

1. guna2018transmembranedomainrecognition pages 4-6
2. hagiwara2023proteotoxicstressesstimulate pages 3-5
3. wang2021analysisofthe pages 80-84
4. hagiwara2023proteotoxicstressesstimulate pages 10-12
5. roboti2022mitochondrialantiviralsignallingprotein pages 1-2
6. carretero2024differentiallunggene pages 8-10
7. abildgaard2020cochaperonesintargeting pages 9-11
8. hagiwara2023proteotoxicstressesstimulate pages 1-3
9. abildgaard2020cochaperonesintargeting pages 21-23
10. roboti2022mitochondrialantiviralsignallingprotein pages 15-15
11. hagiwara2023proteotoxicstressesstimulate pages 14-15
12. https://doi.org/10.1042/BCJ20230267
13. https://doi.org/10.1242/jcs.259596
14. https://doi.org/10.1091/mbc.e22-08-0355
15. https://doi.org/10.1371/journal.ppat.1012110
16. https://doi.org/10.1038/s41423-024-01195-1
17. https://doi.org/10.1371/journal.pone.0309166
18. https://doi.org/10.1016/j.cub.2018.02.004
19. https://doi.org/10.3390/biom10081141
20. https://doi.org/10.1042/bcj20230267,
21. https://doi.org/10.1091/mbc.e22-08-0355,
22. https://doi.org/10.1371/journal.ppat.1012110,
23. https://doi.org/10.1016/j.cub.2018.02.004,
24. https://doi.org/10.3390/biom10081141,
25. https://doi.org/10.1242/jcs.259596,
26. https://doi.org/10.18154/rwth-2022-00532,
27. https://doi.org/10.1038/s41423-024-01195-1,
28. https://doi.org/10.1371/journal.pone.0309166,
29. https://doi.org/10.1042/bcj20190620,